Anti-BCMA/CD19 CAR T Cells With Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy

Researchers conducted a Phase I clinical trial of anti-BCMA CAR T cells with or without anti-CD19 CAR T cells in multiple myeloma patients responding to third- or later- line therapy or high-risk patients responding to first-line therapy, followed by early lenalidomide or pomalidomide maintenance.